# Beijing Tianshi Tongda Pharmaceutical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-tianshi-tongda-pharmaceutical-technology-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Total disclosed funding: $21M
- Latest round: Angel (Jul 5, 2022)
- Investors on record: 3

## About

Established in 2022 and based in Beijing, China, Beijing Tianshi Tongda Pharmaceutical Technology Co., Ltd is a pharmaceutical company focuses on innovative drugs for the precision treatment of self-exempt and inflammatory diseases. Xiaoling Liu will remain as CEO of Beijing Tianshi Tongda Pharmaceutical Technology Co., Ltd. In July 2022, Beijing Tianshi Tongda Pharmaceutical Technology Co., Ltd raised CNY 140 million co led by new investors Redhill Capital and Daokang Zhihe, with participation from new investor CASI Pharmaceuticals.

The company's main business is the research, development production of innovative drugs for the precision treatment of self-exempt and inflammatory diseases.

The company plans to use the angel funding for PAT-A001 was filed for clinical trials in China and the United States, and further expanded the application of HDPM, a precision typing platform, to develop more novel therapies for self-exempt diseases and inflammatory diseases.

## Funding rounds

- Angel, Jul 5, 2022, $21M — CASI Pharmaceuticals, Inc., Redhill Capital, Daokang Zhihe

## Investors

- CASI Pharmaceuticals, Inc. — Angel
- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Angel
- Daokang Zhihe — Angel